175 results about "Diabetic retinopathy" patented technology

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

The invention relates to the technical field of image processing, and particularly discloses a diabetic retinopathy fine-grained grading-oriented self-adaptive multi-scale model, which comprises a layered global context module for fusing multi-scale feature extraction, self-adaptive attention enhancement and dynamic weighted fusion, constructing a global and local information complementary multi-scale representation mechanism, and constructing a multi-scale feature extraction model; feature representation with higher expressive power is generated; the multi-scale adaptive attention module captures a complex dependency relationship among different spatial positions in the feature map through a synergistic effect of multi-scale feature extraction and adaptive attention enhancement; the relation multi-head attention module is used for deeply mining and capturing complex association among different features in a feature map so as to enhance the identification capability and classification performance of the model on fine-grained lesion features; and the attention mechanism module is used for capturing a key channel and an important space region in the feature map by combining a channel and a space attention mechanism so as to comprehensively and finely analyze diversified features of DR lesions.

Provided herein are methods of treating diabetic retinopathy in a subject, comprising administering to the subject a compound of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, p, R1, R2, R3, L1, L2, L3, R4, X1, X2, X3, and X4 are as defined herein.

Provided herein are methods and apparatuses for analyzing mixed formulations of proteins and protein conjugates thereof. Some embodiments of the protein can be conjugated to a moiety, such as a HEMA-PC polymer. Some embodiments of the antibody conjugates can retain or enhance antibody activity. The antibody and conjugate thereof can be particularly useful for treating diabetic retinopathy.

The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, the treatment of ischemic injury, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy, infections of the skin, peripheral vascular disease, stroke, asthma, and the like.

Provided herein are compounds of formula (I'): or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing, wherein n,p, R1a, R1b, R1c, R1d, R2, R3, R4, L1, L2, L3, X1, X2, X3, X4, and X5 are as defined herein. Also provided are methods of preparing compounds of formula (I'), or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing. Also provided are methods of inhibiting APOL1 and methods of treating an APOL1-mediated disease, disorder, or condition, such as kidney disease or diabetic retinopathy, in an individual.

The invention provides a traceable mitochondrial targeting nano system as well as a preparation method and application thereof, and belongs to the field of medicines. The traceable mitochondrial targeting nano system constructed by the invention can continuously release resveratrol and maintain the photochemical stability of resveratrol. The nano system shows efficient cellular uptake and accurate mitochondrial targeting ability, and promotes removal of mitochondrial ROS and adjustment of mitochondrial autophagy, so that vascular leakage and angiogenesis are relieved, in-vivo microvascular hyperplasia and retina degeneration are remarkably inhibited, and the curative effect is improved. The distribution of the compound in fundus can be monitored in real time through clinical ophthalmological diagnosis equipment, and the compound has a good application prospect in preparation of drugs for preventing and / or treating diabetic retinopathy.

The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.

The invention discloses a diabetic retinopathy process simulation method. The method comprises the steps that a two-dimensional discrete coordinate system is constructed, and a blood vessel index function describing unit grid attributes of unit grids is defined; updating the blood glucose concentration, the oxygen concentration, the fibronectin concentration and the growth factor concentration of each unit grid every preset time t; predicting the movement direction of each blood vessel tip in the t time period according to the fibronectin concentration and the growth factor concentration; calculating a first predicted extension distance and a second predicted extension distance according to the motion direction in the current t time period and the motion direction in the last t time period; and updating the unit grid attribute of each unit grid in the two-dimensional discrete coordinate system according to the movement direction in the t time period, the blood vessel existence time of the blood vessel tip and the movement extension distance calculated by the blood vessel tip. According to the method, the oxygen concentration and the blood glucose concentration are incorporated into the model for simulating vascular extension, and accurate simulation prediction of diabetic retinopathy is achieved.

Provided herein are compounds of formula (I'): or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing, wherein X1, X2, X3, X4, R1, R2, Y1, Y2, Y3, m,p, r, s, t, and ring A are as defined herein. Also provided are methods of preparing compounds of formula (I), or stereoisomers or tautomers thereof, or pharmaceutically acceptable salts of any of the foregoing. Also provided are methods of inhibiting AP0L1 and methods of treating an AP0L1 -mediated disease, disorder, or condition, such as kidney disease or diabetic retinopathy, in an individual.

The present invention relates to a protein tyrosine kinase inhibitor for the treatment of protein tyrosine kinase-mediated proliferative diseases or symptoms, for example ocular diseases including pathological neovascularization, retinal ischemia, retinal edema, and diabetic retinopathy, as well as malignant tumors. More particularly, the present invention relates to a compound with protein tyrosine kinase inhibitory activity and / or improved solubility and ocular bioavailability, and its uses in the treatment of ocular diseases and malignant tumors.

The present invention relates to a weakly supervised learning diabetic retinopathy grading and lesion identification method and system, the method comprising: S1: inputting a diabetic retinopathy fundus color image into a CNN network to obtain a feature map F; inputting F into a lesion point capture module based on weakly supervised object positioning, selecting to enter a branch module, calculating a score map, multiplying the score map with the feature map F to obtain a new feature map F'; S2: using an optimal network structure search module based on reinforcement learning to calculate the insertion position, selection probability, feature discarding threshold and retention threshold of the weakly supervised lesion point capture module in the CNN network, and finally outputting the feature map F. NA S3: Lesion attribute prediction and disease classification are obtained through attribute mining and lesion identification modules. S4: Based on the results of S3, the final lesion identification result is obtained through multiple iterative erasure calculations. The method provided by the present invention can improve the effectiveness of lesion capture and use lesion mining methods to determine lesion type, providing a basis for disease classification.

The present invention relates to a composition for preventing or treating diabetic retinopathy, comprising a peptide having an excellent effect of inhibiting the generation of neovascularization in the retina, the loss of perivascular cells, and the expansion of blood vessels. The present invention can be effectively used in the prevention or treatment of retinopathy by inhibiting increase in vascular permeability, inflammation, and the occurrence of neovascularization.

The present disclosure relates to the pharmaceutical use of antagonists (e.g., antibodies or antigen-binding portions thereof) that specifically bind to FAM19A5 for the treatment of retinopathy (e.g., diabetic retinopathy) and / or maculopathy (e.g., age-related macular degeneration) in an individual in need thereof.

This invention relates to pharmaceutical compositions and methods for treatment of ophthalmic or ocular diseases and conditions. The compositions contain targeting molecules that are made up of a bifunctional hepatoma-derived growth factor-specific antibody covalently attached to a trapper that specifically binds vascular endothelial growth factor and / or transforming growth factor beta. Specific eye conditions that can be beneficially affected by the compositions and methods of the invention include age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathy, and retinal vein occlusion.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary diseases, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension, Alzheimer disease, vascular dementia, glaucoma, diabetic retinopathy, retinopathy of prematurity, retinal vein occlusion, ischemic optic neuropathy or chronic kidney disease. The present invention relates to a compound of the formula [I], the formula [II] or the formula [III], or a pharmaceutically acceptable salt thereof:wherein each symbol is as defined in the DESCRIPTION.

Compositions and methods are described for the delivery of a fully human post-translationally modified (HuPTM) monoclonal antibody (“mAb”) or the antigen-binding fragment of a mAb against human vascular endothelial growth factor (“hVEGF”)—such as, e.g., a fully human-glycosylated (HuGly) anti-hVEGF antigen-binding fragment—to the retina / vitreal humour in the eye(s) of human subjects diagnosed with ocular diseases caused by increased neovascularization, for example, neovascular age-related macular degeneration (“nAMD”), also known as “wet” age-related macular degeneration (“WAMD”), age-related macular degeneration (“AMD”), and diabetic retinopathy.

We provide TRPC5 inhibitors for use in treating or reducing the risk of developing kidney disease, diabetic retinopathy, anxiety disorders, depression, or cancer. [Solution] Compounds according to formula (I) or (II), and pharmaceutical compositions containing them are disclosed. A therapeutic method using a compound of formula (I) or (II) to treat, for example, kidney disease is also disclosed. JPEG2026086459000081.jpg3992

The present disclosure relates to methods and systems for quantifying the vascular pattern using ocular imaging that shows vessel profiles for the detection, prevention, and treatment of diabetic retinopathy and other related ocular vascular diseases.

The present invention relates to a method for processing diabetic retinopathy image data, and the method includes: data preprocessing: obtaining a high-definition fundus image X, obtaining a preprocessed high-definition fundus image #imgabs0# through noise reduction and detail enhancement, and then obtaining a preprocessed high-definition fundus image #imgabs1# with a smaller resolution through scaling and data enhancement; feature extraction: inputting the preprocessed high-definition fundus image #imgabs2# with a smaller resolution into a convolutional neural network A to obtain a feature map F; respectively adopting an overall processing branch processing method and a region of interest processing branch processing method to obtain a global processing result y whole and a region of interest processing result y attention ; averaging the scores of the global processing result y whole and the region of interest processing result y attention to obtain a final processing result y pred . Compared with the prior art, the present invention has the advantages of high accuracy, high robustness, and saving computing resources.

The present invention relates to novel compounds and pharmaceutical compositions thereof, and to methods for promoting healthy skin aging, treating skin disorders, treating cardiovascular disorders, treating renal disorders, treating angiogenesis disorders, such as cancer, treating tissue damage, such as non-cardiac tissue damage, treating progressive myocardial infarction, and treating various other disorders, such as complications resulting from diabetes with the compounds and compositions of the invention. Other disorders may include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, skin infections, peripheral vascular disease, stroke, and the like.

Provided herein are methods of treating diabetic retinopathy in a subject, comprising administering to the subject a compound of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m, n, p, R1, R2, R3, L1, L2, L3, R4, X1, X2, X3, and X4 are as defined herein.

3-[(3S,4R)-3-Methyl-6-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile suppresses an increase of the retinal vascular permeability induced by VEGF, it can be used as an active ingredient of a therapeutic or preventive agent for various eye diseases involving VEGF, such as age-related macular degeneration, diabetic retinopathy, macular edema, neovascular maculopathy, retinal vein occlusion and neovascular glaucoma.

The present application relates to the technical field of biological medicine, and particularly relates to application of Crybb2 recombinant protein in treatment and / or prevention of diabetic retinopathy. The present application finds that the use of Crybb2 recombinant protein can improve the activity of müller cells, reduce the level of GFAP, restore the level of GS, reduce inflammation, reduce apoptosis of retinal cells and restore the structure and function of the retina. It can be used for treatment and / or prevention of diabetic retinopathy.

The invention provides an application of USP7 (ubiquitin-specific protease 7) as a target spot in preparation of drugs for treating vascular abnormal leakage diseases, and relates to the technical field of biomedicine, USP7 (ubiquitin-specific protease 7) as a deubiquitination enzyme not only regulates tumor, nerve and immune related diseases, but also is closely related to vascular endothelial cell functions. In the vascular homeostasis, the USP7 can maintain the integrity of a vascular barrier and inhibit pathological leakage by stabilizing endothelial connexin such as VE-cadherin and beta-catenin; under the inflammation or hypoxia condition, through deubiquitination of HIF-1alpha or NF-kappa B pathway components (such as I kappa B alpha), vascular endothelial cell activation can be promoted, VEGF signal-driven abnormal angiogenesis or release of inflammatory factors can be aggravated, and diabetic retinopathy, tumor vascular hyperplasia and sepsis-related vascular leakage can be participated. According to the application, verification experiments prove that USP7 has a certain protection effect on vascular permeability, and a treatment strategy is provided for vascular abnormal leakage diseases clinically.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof:wherein each symbol means the same as that described in the specification.

The present invention discloses a biomarker, a detection reagent and its application related to diabetic retinopathy. The biomarker related to diabetic retinopathy includes circ_0053004, and the nucleotide sequence of circ_0053004 is shown in SEQ ID No. 1. In the present invention, the change in the expression level of circ_0053004 is significantly correlated with the occurrence of diabetic retinopathy. It can be used as a biomarker for the early diagnosis of diabetic retinopathy, regularly assessing the progression of diabetic retinopathy and the recurrence after treatment, and providing an important reference basis for the early diagnosis, prognosis and early intervention treatment of diabetic retinopathy. It has great practical clinical value, can intervene and treat early, and reduce unnecessary treatment and expenses for patients who are not at high risk of recurrence.

Methods are provided to prevent and to treat diabetic retinopathy by using Calcium channel blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, or angiotensin receptor blockers (ARB), and more particularly, to a method to prevent and treat diabetic retinopathy by using calcium channel blockers, Angiotensin-Converting Enzyme Inhibitors, or angiotensin receptor blockers that may not need to be taken orally, but may also be administered by ophthalmic preparation directly onto or into the eye where diabetic retinopathy is formed, to increase the capillary network and augment the blood supply to the anatomy of the eye.

The present invention relates to superoxide dismutase and uses thereof for preventing or treating diabetic retinopathy or uveitis. The superoxide dismutase according to the present invention can be effectively used in the prevention or treatment of diabetic retinopathy or uveitis, particularly through oral administration.

Provided are MTSP-1 polypeptides modified to have altered activity and / or specificity so that they cleave a complement protein, such as complement protein C3, to inhibit its activity and thereby inhibit complement activation. The modified MTSP-1 polypeptides that inhibit complement activation can be used for treatment of diseases and conditions in which complement activation plays a role. Such diseases and conditions include inflammatory diseases and diseases with an inflammatory component. Exemplary of these disorders are ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, ophthalmic disorders, such as diabetic retinopathies and macular degeneration, including age-related macular degeneration (AMD), and transplanted organ rejection, such as renal delayed graft function (DGF).